Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors -- drugs that take the brakes ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Visit https://www.apbioinc.com/en/ for more information about AP Biosciences and its pipeline of next-generation cancer therapies.

The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be ...

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...

Prostate cancer is the most common cancer in men worldwide. Thanks to scientific breakthroughs, there are more ways than ever to treat it — especially when it’s caught early. One ...

DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting it exclusive rights to leverage its antibody ...

Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors — drugs that take the brakes off ...

Millions of dollars earmarked for fighting a form of rare and deadly children’s cancer is sitting unused, with advocates and ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...